Yıldırım Derya, Kardaş Rıza Can, Özkızıltaş Burcugul, Vasi İbrahim, Küçük Hamit, Öztürk Mehmet Akif, Tufan Abdurrahman
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey.
Eur J Rheumatol. 2023 Jan;10(1):29-33. doi: 10.5152/EuJRheum.2022.21180.
Patients with familial Mediterranean fever and spondylitis often fail to respond to conventional and biologic therapies. Achieving remission in these patients usually requires conventional and biologic treatment combinations. Combination of biologic agents may be a promising option for patients with familial Mediterranean fever and spondylitis who have refractory disease. Until recently, limited evidence existed regarding the efficacy and safety of this treatment strategy. To address this, our report presented a case series of 4 patients with familial Mediterranean fever and spondylitis who were resistant to standard treatments and in whom remission is achieved only with dual biologic therapy. The authors also conducted a literature search for studies that reported dual biological therapy in inflammatory diseases.
患有家族性地中海热和脊柱炎的患者通常对传统疗法和生物疗法没有反应。在这些患者中实现缓解通常需要传统疗法和生物疗法联合使用。对于患有难治性疾病的家族性地中海热和脊柱炎患者，生物制剂联合使用可能是一种有前景的选择。直到最近，关于这种治疗策略的疗效和安全性的证据还很有限。为了解决这个问题，我们的报告介绍了一个病例系列，其中4例家族性地中海热和脊柱炎患者对标准治疗有抵抗性，仅通过双重生物疗法才实现缓解。作者还对报告了在炎症性疾病中使用双重生物疗法的研究进行了文献检索。
